Get the Stockscreener App
2.63
1.50%
-0.04
Tvardi Therapeutics Inc stock is traded at $2.63, with a volume of 39,740.
It is down -1.50% in the last 24 hours and down -34.25% over the past month.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
See More
Previous Close:
$2.67
Open:
$2.63
24h Volume:
39,740
Relative Volume:
0.77
Market Cap:
$24.67M
Revenue:
$2.14M
Net Income/Loss:
$-15.44M
P/E Ratio:
-0.8499
EPS:
-3.0946
Net Cash Flow:
$-24.67M
1W Performance:
-5.40%
1M Performance:
-34.25%
6M Performance:
-37.38%
1Y Performance:
-89.46%
1-Day Range:
$2.57
$2.69
1-Week Range:
$2.57
$2.895
52-Week Range:
$2.57
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Name
Tvardi Therapeutics Inc
Sector
Industry
Phone
(713) 489-8654
Address
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
2.63 | 25.05M | 2.14M | -15.44M | -24.67M | -3.0946 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-14-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-14-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Oct-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-14-25 | Initiated | Raymond James | Outperform |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | Piper Sandler | Overweight |
| May-21-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Initiated | BTIG Research | Buy |
| Jun-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-13-24 | Downgrade | Needham | Buy → Hold |
| Jun-13-24 | Downgrade | Stifel | Buy → Hold |
| Mar-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-08-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-01-21 | Resumed | Canaccord Genuity | Buy |
| Aug-03-21 | Initiated | JP Morgan | Neutral |
| Apr-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-19 | Reiterated | H.C. Wainwright | Buy |
| May-29-19 | Reiterated | Laidlaw | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Jan-15-19 | Initiated | BofA/Merrill | Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Jefferies | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jun-28-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-12-18 | Resumed | H.C. Wainwright | Buy |
| Feb-12-18 | Upgrade | Janney | Neutral → Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
View All
Tvardi Therapeutics Inc Stock (TVRD) Latest News
Tvardi Therapeutics (TVRD) Slides as Stock Approaches Key Support Near $2.51Fibonacci Time Zone - newsline.com
TVRD Q1 2026 Earnings: Narrowed Loss Per Share Beats Expectations Amid Pipeline ProgressHealthcare Earnings Report - newsline.com
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures - TipRanks
Tvardi Therapeutics (TVRD) grants 6,000 stock options to director - Stock Titan
Tvardi Therapeutics (TVRD) director granted 6,000 options at $2.78 exercise price - Stock Titan
Tvardi Therapeutics (TVRD) director Sujal Shah awarded 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) director receives grant of 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) director awarded 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) investors approve directors, say-on-pay and Deloitte as 2026 auditor - Stock Titan
Tvardi Therapeutics (TVRD) Declines 2.88% as Stock Tests Key Support; Near-Term Outlook Hinges on $2.56 FloorFactor Momentum - newsline.com
This Cerebras Systems analyst begins coverage on a bullish note; here are top 3 initiations for Monday - MSN
H.C. Wainwright initiates Tvardi Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright initiates Tvardi Therapeutics stock with buy rating - Investing.com
HC Wainwright Initiates Tvardi Therapeutics at Buy With $9 Price Target - Moomoo
H.C. Wainwright Initiates Tvardi Therapeutics(TVRD.US) With Buy Rating, Announces Target Price $9 - Moomoo
Tvardi Therapeutics: STAT3 inhibitor TTI-109 aims to address fibrosis and immune disorders, with key data expected soon - TradingView
Tvardi Therapeutics: STAT3 inhibitor programs advance with new data expected, targeting fibrosis and immune disorders - TradingView
MSN Money - MSN
TVRD Q1 2026 Earnings: Net Loss Narrows as Clinical Pipeline AdvancesEarnings Beat Streak - newsline.com
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Tvardi Therapeutics (TVRD) Declines 4%: Support at $3.18 in FocusVWAP Deviation - newsline.com
Tvardi Therapeutics (TVRD) Holds Steady Near Support Amid Low-Volume TradingShort Setup Alerts - The Legal Advocate
Tvardi Therapeutics Q1 2026 Earnings: Narrower-than-expected loss as pipeline advancesEarnings Manipulation Risk - Newser
Tvardi Therapeutics to Participate in Upcoming Investor Events - GlobeNewswire
Tvardi Therapeutics (TVRD) Trading at $4.00 — Key Decision Point 2026-05-18Institutional Volume - The Legal Advocate
What Tvardi Therapeutics (TVRD)'s +1.01% Jump Means for Investors 2026-05-17Market Neutral Pair - Newser
[EFFECT] Tvardi Therapeutics, Inc. SEC Filing - Stock Titan
Cantor Fitzgerald Sticks to Their Hold Rating for Tvardi Therapeutics (TVRD) - The Globe and Mail
Barclays Maintains Tvardi Therapeutics(TVRD.US) With Sell Rating, Maintains Target Price $3 - Moomoo
Number of shareholders of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
593,758 resale shares by Tvardi Therapeutics (NASDAQ: TVRD) post‑merger - Stock Titan
Tvardi Therapeutics 4Q Research and Development Expenses $4.9M >TVRD - Moomoo
Tvardi Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Tvardi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Tvardi Therapeutics 1Q 2026: Revenue ($6.81M), Net income ($6.8M), EPS ($0.73) — 10-Q Summary - TradingView
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update - The Manila Times
Tvardi Therapeutics: Net loss narrowed to $6.8M, but continued operations depend on securing additional funding - TradingView
Tvardi Therapeutics: Net loss narrowed in Q1 2026 as clinical milestones for TTI-109 and TTI-101 approach - TradingView
Tvardi: Q1 Earnings Snapshot - marketscreener.com
Tvardi Therapeutics (NASDAQ: TVRD) posts Q1 2026 loss and warns on going concern - Stock Titan
Tvardi Therapeutics (NASDAQ: TVRD) narrows Q1 loss and targets 2026 STAT3 trial readouts - Stock Titan
Two biotech readouts ahead as Tvardi says cash lasts into Q4 - Stock Titan
Tvardi Therapeutics Inc Stock (TVRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):